Cancer
Conditions
Brief summary
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but life-threatening adverse events such as myelodysplastic syndrome (MDS) and/or acute myeloid leukaemia (AML). Today, data about MDS/AML are scarce. The objective was to investigate reports of MDS/AML adverse events related to PARPi, including olaparib, rucaparib, niraparib, talazoparib and veliparib using the World Health Organization (WHO) and the French pharmacovigilance databases.
Detailed description
Here, investigators use the World Health Organization (WHO) and the French database of individual safety case reports, to identify cases of MDS/AML related to PARPi.
Interventions
DRUGPARP Inhibitors
olaparib, rucaparib, niraparib, talazoparib, veliparib
Sponsors
University Hospital, Caen
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Case reported in the World Health Organization (WHO, also called VigiBase) or French database of individual safety case reports at the time of the extraction, * Patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib (none).
Exclusion criteria
* Chronology not compatible between the PARPi and adverse event (MDS/AML)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MDS/AML reports related to PARPi (from WHO database). | From inception to May 3, 2020 | Identification of the MDS and/or AML adverse event related to PARP inhibitors reported in the World Health Organization (WHO) database of individual safety case reports. |
| MDS/AML reports related to PARPi (from French database). | From inception to May 1, 2021 | Identification of the MDS and/or AML adverse event related to PARP inhibitors reported in the French pharmacovigilance database of individual safety case reports. The aim is to describe clinical features of these rare adverse events, including bone marrow analyzes, cytogenetic and molecular abnormalities, blasts immunophenotyping anonymously reported in this database. |
Secondary
| Measure | Time frame |
|---|---|
| Description of the median time to onset since first PARPi exposure. | From inception to May 3, 2020 |
| Description of the fatality rate. | From inception to May 3, 2020 |
| Description of patients who experienced co-reported adverse events. | From inception to May 3, 2020 |
Countries
France
Outcome results
None listed